ERBB2 and neoplasm: We note, however, that the sustained response in our index patient is correlated with the dramatic decline in HER2 MAF, with a more modest response to ER targeting fulvestrant, raising the possibility that HER2-activated tumor clones may contribute disproportionately to tumor proliferation and expansion in this patient.